南微医学(688029) - 2025 Q4 - 年度业绩
MTMMTM(SH:688029)2026-02-27 08:30

Financial Performance - In 2025, the company achieved total revenue of RMB 319,093.19 million, representing a growth of 15.81% compared to the previous year[6] - The net profit attributable to the parent company's shareholders reached RMB 57,011.40 million, an increase of 3.05% year-on-year[6] - The total assets at the end of the reporting period were RMB 543,404.00 million, up 13.69% from the beginning of the period[6] - The equity attributable to the parent company's shareholders increased by 7.38% to RMB 410,853.20 million[6] - The company's basic earnings per share rose to RMB 3.05, a 3.39% increase from RMB 2.95 in the previous year[3] - The weighted average return on net assets decreased by 0.48 percentage points to 14.37%[3] Business Strategy - The company is transitioning its overseas business from a distribution phase to a localized direct sales phase, enhancing its competitive advantage[7] - The revenue growth was primarily driven by overseas business and new product launches, effectively countering short-term pressures from centralized procurement and tariffs[9] - The company plans to continue its dual strategy of internationalization and innovation, with a focus on new product launches and investment projects in 2026[7] Challenges - The company faced profit growth challenges due to decreased gross margins from key products and increased costs related to overseas investment projects[9]

MTM-南微医学(688029) - 2025 Q4 - 年度业绩 - Reportify